Clinical Trials Browser

Phase 2 × Has results × palbociclib × Clear all

NCT04439201 2026-03-18

Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)

Phase 2 Active not recruiting

40 enrolled 9 charts

LymphoidOther hematologic neoplasm

Lymphoma, Hematologic Neoplasms

NCT06390839 2026-03-17

Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C)

Phase 2 Active not recruiting

43 enrolled 10 charts

Lymphoma

NCT03446157 2026-03-10

Palbociclib and Cetuximab in Metastatic Colorectal Cancer

Phase 2 Completed

24 enrolled 14 charts

Gastrointestinal

Colonic Neoplasms

NCT02778685 2026-02-24

Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer

Phase 2 Active not recruiting

47 enrolled 17 charts

Breast Neoplasms

NCT02668666 2026-01-20

Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer

Phase 2 Completed

49 enrolled 14 charts

Breast Neoplasms

NCT01723774 2025-12-09

PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

Phase 2 Active not recruiting

84 enrolled 17 charts

Breast Neoplasms

NCT02630693 2025-11-25

Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer

Phase 2 Completed

180 enrolled 14 charts

Breast Neoplasms

NCT03147287 2025-09-30

Palbociclib After CDK and Endocrine Therapy (PACE)

Phase 2 Active not recruiting

220 enrolled 11 charts

Breast Neoplasms

NCT03535506 2025-09-26

WI223281

Phase 2 Terminated

17 enrolled 9 charts

Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT01907607 2025-08-24

CYCLIGIST

Phase 2 Completed

29 enrolled 8 charts

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT01356628 2025-07-28

A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer

Phase 2 Completed

23 enrolled 12 charts

Gastrointestinal

Liver Neoplasms

NCT02764541 2025-05-07

Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)

Phase 2 Active not recruiting

195 enrolled 26 charts

Breast Neoplasms, Carcinoma, Lobular

NCT02040857 2025-04-29

Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer

Phase 2 Completed

162 enrolled 12 charts

Breast Neoplasms

NCT03389477 2025-04-13

Los Tres Paso: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma

Phase 2 Active not recruiting

26 enrolled 12 charts

Squamous Cell Carcinoma of Head and Neck

NCT03691493 2025-02-17

ASPIRE

Phase 2 Completed

36 enrolled 17 charts

Breast Neoplasms

NCT04256941 2024-12-27

Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study

Phase 2 Terminated

4 enrolled 7 charts

Breast Neoplasms

NCT03644186 2024-12-13

TOUCH

Phase 2 Completed

147 enrolled 11 charts

Breast Neoplasms

NCT02491983 2024-12-09

PARSIFAL

Phase 2 Completed

486 enrolled 15 charts

Breast Neoplasms

NCT02530320 2024-11-22

Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved

Phase 2 Completed

34 enrolled 13 charts

Astrocytoma, Oligodendroglioma

NCT03526250 2024-11-01

Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)

Phase 2 Completed

23 enrolled 11 charts

CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

Familial ependymoma, Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

NCT03981614 2024-08-22

Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer

Phase 2 Completed

102 enrolled 11 charts

Gastrointestinal

Colorectal Neoplasms

NCT04129151 2024-08-01

Palbociclib + Ganitumab In Ewing Sarcoma

Phase 2 Terminated

10 enrolled 15 charts

Recurrence, Sarcoma, Sarcoma, Ewing

NCT03007979 2024-03-20

Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer

Phase 2 Completed

55 enrolled 15 charts

Breast Neoplasms

NCT02536742 2024-02-26

PYTHIA

Phase 2 Completed

124 enrolled 10 charts

Breast Neoplasms, Neoplasm Metastasis

NCT02499120 2023-09-08

Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer

Phase 2 Completed

125 enrolled 21 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT02384239 2022-03-16

A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer

Phase 2 Completed

70 enrolled 16 charts

Breast Neoplasms

NCT02296801 2022-01-13

PALLET

Phase 2 Completed

307 enrolled 18 charts

Breast Neoplasms

NCT03633331 2021-10-15

Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer

Phase 2 Unknown

93 enrolled 8 charts

Estrogen Receptor-positive Breast Cancer

NCT02907918 2021-09-29

PALTAN

Phase 2 Terminated

26 enrolled 8 charts

Breast Neoplasms

NCT03194373 2021-04-12

Phase II Trial Evaluating the Efficacy of Palbociclib in Combination With Carboplatin for the Treatment of Unresectable Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase 2 Completed

21 enrolled 10 charts

Squamous Cell Carcinoma of Head and Neck

NCT01684215 2020-11-23

A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer

Phase 2 Completed

61 enrolled 45 charts

Breast Neoplasms, Neoplasms

NCT02059213 2020-09-16

A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer

Phase 2 Completed

72 enrolled 15 charts

Prostatic Neoplasms

NCT02774681 2020-04-14

Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis

Phase 2 Terminated

12 enrolled 11 charts

Breast Neoplasms

NCT01209598 2017-11-06

PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma

Phase 2 Completed

90 enrolled 7 charts

Liposarcoma, Sarcoma

NCT01291017 2016-05-13

Cyclin Dependent Kinase (CDK)4/6 Inhibitor, PD0332991 in Advanced Non-small Cell Lung Cancer NSCLC.

Phase 2 Completed

19 enrolled 8 charts

Carcinoma, Non-Small-Cell Lung

NCT00555906 2015-03-19

An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.

Phase 2 Completed

53 enrolled 18 charts

Multiple Myeloma